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Chemiluminescence and superoxide anion production by leuko-
cytes from chronic hemodialysis patients. During phagocytosis or
in response to a soluble stimulus, polymorphonuclear leukocytes
(PMN) undergo a burst of oxidative metabolism involved in-
timately in antimicrobial activity. Superoxide anion produced
during the burst is bactericidal either directly or as an inter-
mediate metabolite. In addition, stimulated PMN's emit light or
chemiluminescence (CL). CL is a sensitive measure of PMN
oxidative potential and correlates with antimicrobial activity.
Because of the increased susceptibility to infection observed in
patients on chronic hemodialysis (CHD), we studied superoxide
anion production and luminol-amplified CL in PMN's from CHD
patients and in age-matched controls in the resting state and in
response to phorbol myristate acetate (PMA). Studies in autolo-
gous serum showed higher CL resting values in PMN's from
CHD patients, and crossincubation studies indicated that this is a
result of factor(s) in the patients' serum. In response to PMA,
PMN's from patients on CHD in autologous serum had sig-
nificantly (P <0.05) less of an increase (phorbol-stimulated
minus resting values) in CL as compared with controls (peak
time values, 60 5 x l0 cpm for patients vs. 76 5 x 10 cpm
for controls). With crossincubation studies, these differences
persisted, suggesting that there is a defect intrinsic to the patient
PMN. Studies done after dialysis showed a significant reduction
in resting values. The decreased response to PMA stimulation
remained, however. No difference in superoxide anion produc-
tion (superoxide-dismutase-inhibitable ferricytochrome c reduc-
tion) was seen in PMN's from patients on CHD compared with
controls. This along with other studies indicating normal nitro-
blue tetrazolium (NBT) reduction in PMN's from CHD patients
indicates that the decreased CL is due to superoxide-anion-inde-
pendent mechanisms. Because CL correlates well with anti-
microbial activity, the reduced response to PMA observed in
neutrophils from patients on CHD may explain, at least in part,
the increased susceptibility to infection in these patients.
Chémilummescence et production d'anion superoxyde par les
leucocytes obtenus de malades en hémodialyse. Au cours de Ia
phagocytose ou en réponse a un stimulus soluble les poly-
nucléaires (PMN) subissent une poussée du métabolisme oxyda-
tif qui est intimement impliqué dans l'activité antimicrobienne.
L'anion superoxyde produit au cours de Ia poussée est bactéri-
cide soit directement soit comme métabolite intermédiaire. De
plus les PMN stimulés émettent de Ia lumière (chémilumines-
cence CL). La CL est une norme sensible du potentiel oxydatif
de PMN, elle est corrélée a l'activité antimicrobienne. En raison
de la fragilité vis-à-vis des infections observée chez les malades
en hémodialyse chronique (CHD), nous avons étudié la produc-
tion d'anion superoxyde et Ia CL amplifiée par le luminol dans
les PMN de malades en CHD et de contrôles d'âges adéquats au
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cours de l'état basal et en réponse au PMA. Les mesures en
serum autologue ont montré des valeurs basales de CL plus éle-
vCes pour les malades en CHD et les mesures au cours d'in-
cubations croisées indiquent que ceci résulte de La presence
d'un ou plusieurs facteurs dans le serum des malades. En ré-
ponse a PMA les PMN des malades en CHD dans du serum auto-
logue ont significativement moms (P < 0,05) d'augmentation (Va-
leur au cours de Ia stimulation par Ic phorbol diminuée des va-
leurs basales) de la CL que les contrôles (valeur de pic 60 5 Xl0 cpm pour les malades contre 76 5 x 10 cpm pour les con-
trôles). Au cours des incubations croisées ces differences per-
sistent, cc qui suggère qu'il y a un deficit propre aux PMN des
malades. Les mesures faites aprCs dialyse montrent une diminu-
tion significative des valeurs basales. La diminution de la ré-
ponse ala stimulation par PMA persiste cependant. II n'a pas été
observe de difference dans Ia production d'anion superoxyde
(reduction du ferricytochrome C inhibée par La superoxyde dis-
mutase) dans les PMN des malades en CHD par comparaison
avec les contrôles. Cela rejoint la conclusion d'autres etudes sc-
ion lesquelles La reduction normale de NBT dans les PMN des
malades en CHD indique que la diminution de CL est liée a des
mécanismes indépendants de l'anion superoxyde. Puisque CL
est bien corrélée a l'activité antimicrobienne La réponse dimin-
uée a PMA observCe dans les polynucléaires des malades en
CFID peut expliquer, au moms en partie, la susceptibiité accrue
de ces malades aux infections.
Infection persists as a cause of significant morbid-
ity and mortality in patients undergoing chronic he-
modialysis (CHD) [1-3]. The major role played by
the polymorphonuclear leukocyte (PMN) in anti-
microbial response by the host has encouraged con-
siderable study of several aspects of neutrophil
function in the CHD patient, including chemotaxis
[47] and phagocytosis [8—11].
During phagocytosis, the PMN undergoes a strik-
ing increase in oxidative metabolism known as the
respiratory burst. The respiratory burst occurs
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through activation of a single enzyme system and
consists of increased oxygen uptake, activation of
the hexose monophosphate shunt, production of
several oxygen metabolites (including superoxide
anion, hydrogen peroxide, hydroxyl radical, and
singlet oxygen) [12-14], and is accompanied by light
emission or chemiluminescence (CL) [12, 15, 16].
Originally, the increased oxygen uptake was
thought to be required for phagocytosis. It has been
shown, however, that the phagocytosis can occur in
anaerobic environment [17] and that the respira-
tory burst can be initiated by several soluble stimuli
including phorbol myristate acetate (PMA)
[18], fluoride [19], and cytochalasin E 120]. Most of
the increased oxygen uptake during respiratory
burst is utilized by the enzyme system to catalyze
one-electron reduction of oxygen to superoxide ani-
on by using NADPH as the electron donor [211:
202 + NADPH — 20 + NADP + H
The superoxide anion produced is the major
source of hydrogen peroxide through a dismutation
reaction [12, 14, 21] and also appears to be an inter-
mediate metabolite for the formation of hydroxyl
radical [14, 22-24] (perhaps through modified Haber
Weiss reaction [14]) and singlet oxygen [12, 14]. Su-
peroxide anion [23, 25-27], hydrogen peroxide
(which participates in the well established myelo-
peroxidase-hydrogen peroxide-halide antimicrobial
system) [14, 26, 27], and hydroxyl radical [14, 23,
26-28] have been shown to be antimicrobial.
The purpose, then, of the respiratory burst is to
provide a battery of oxidizing agents that can be
used by the phagocyte for killing microorganisms.
The importance of the respiratory burst in anti-
microbial activity is demonstrated most clearly in
patients with chronic granulomatous disease who
have normal cell motility, phagocytosis, and de-
granulation, but whose cells are unable to mount a
respiratory burst leading to a marked impairment of
the ability of the phagocyte to kill certain species of
bacteria [13, 29].
In response to phagocytosis or soluble stimuli,
PMN's also emit light or CL [12, 15, 16]. The gener-
ation of CL by PMN's is dependent on a complex
relationship between cellular activation and a series
of enzymic and nonenzymic reactions, ultimately
resulting in the production of electronically excited
states, which, on relaxation to ground state, emit
light [16]. Although the precise mechanisms are not
known, the generation of CL by PMN's appears to
depend on production of several species of oxygen,
including superoxide anion, hydrogen peroxide, hy-
droxyl radical, and singlet oxygen, which then in-
teract with other cell constituents and excitable
substrates resulting in the final CL observed [30—
32].
Although the CL from stimulated PMN's is easily
measurable, the addition of luminol (5-amino-2,3-di-
hydro-1,4-phthalazinedione) to thesystem marked-
ly amplifies the CL response, resulting in even
greater sensitivity compared with native CL [16].
Because luminol does not penetrate the leukocytes,
only the extracellular phenomenon is amplified.
Due to its sensitivity and simplicity, CL has been
used to assess the oxidative metabolic potential of
PMN's [16, 33-36] and to assess oponsophagocytic
activity [16, 37, 38]. In addition, the diminished CL
response correlates well with the impaired anti-
microbial activity not only in PMN's from patients
with chronic granulomatous disease [33] but also
when the production of superoxide anion and hy-
drogen peroxide are normal (for example, myelo-
peroxidase (MPO) -deficient PMN 's and in pres-
ence of azide, which inhibits MPO) [39, 40].
In the present study, light emission in the resting
state and in response to a soluble stimulus, PMA,
was examined in PMN's from patients on CHD and
from age-matched controls. In addition, resting and
stimulated superoxide anion production also were
examined in patient and control PMN' s.
Methods
Venous blood was obtained from patients either
just prior to dialysis or, in certain studies, just alter
hemodialysis, and from age-matched healthy adult
volunteers. All subjects provided informed consent
to participate in the study. Patients were taken off
medications for 1 to 3 days prior to study and had
no clinical evidence of infection.
Preparation of leukocytes. Siliconized glassware
and plastic materials were used throughout. Hepa-
rinized venous blood was mixed gently with equal
volumes of 6% dextran (wt/vol) in 0.9% saline (Ab-
bott Laboratories, North Chicago, Illinois) and was
allowed to sediment at room temperature for 45
mm. The leukocyte-rich plasma was centrifuged at
x 120g for 10 mm to separate granulocytes from the
bulk of mononuclear cells and platelets [41]. The
cells were resuspended in 0.2% sodium chloride for
30 sec to lyse erythrocytes, and isotonicity was re-
stored with an equal volume of 1.6% sodium chlo-
ride. Hypotonic lysis was repeated until there were
no visible red cells [42] (generally three times), and
the cells were resuspended in Hank's balanced salt
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solution (HBSS) (Grand Island Biological Compa-
ny, Grand Island, New York). Cells were counted
with both the improved Neubauer hemacytometer
and model ZF Coulter counter, and final suspen-
sions were adjusted to give 1 x 107/ml. Cell viability
was determined using trypan blue exclusion and
was  95%. Differential cell counting, with Wright's
stain, showed leukocyte preparations to be 85%
PMN's with the majority of contaminating cells be-
ing lymphocytes. Fewer than 1 platelet per 50 white
cells were present, and there were essentially no
red blood cells. There was no difference between
preparations from patients and controls with respect
to either purity or viability.
PMN's from CHD patients and controls were
prepared on the same day in parallel and used in the
same assay for measurement of superoxide anion
production and light emission.
Chemiluminescence (CL). CL measurements
were carried out at ambient temperature (20 to 22°
C) in a dark room illuminated with red light. Reac-
tions were carried out in dark-adapted 20-ml glass
scintillation vials. CL was measured with a Beck-
man liquid scintillation system, model 9000, oper-
ated in the out-of-coincidence summation mode as
originally described by Stanley and Williams [43]. A
standard reaction mixture of 10% fresh serum, 50 1d
of luminol (Sigma Chemical Co., St. Louis, Missou-
ri) (final concentration, 1.5 X 10 M) and HBSS
sufficient to make the final volume 2 ml was added
to each vial. Under these conditions, vials contain-
ing only HBSS, serum, and luminol ranged between
4000 and 6000 cpm. To each vial, 1 x 106 cells were
added, and a second count was taken. PMA (12-0-
tetradeconoyl-phorbol- 13-acetate; Consolidated Mid-
land Chemical Co., Brewster, New York) at a final
concentration of 5 sgJml, or, to obtain resting val-
ues, dimethylsulfoxide (DMSO, Fisher Scientific
Co., Pittsburgh, Pennsylvania) was added and
counts were obtained at 10-mm intervals up to 60
mm. Counts from duplicate tubes were averaged.
Measurement of superoxide anion. The genera-
tion of superoxide anion by PMN's was estimated
by a modification of the method of Curnutte and Ba-
bior [41]. In this assay, the superoxide-dismutase
(SOD) -inhibitable reduction of ferricytochrome c
by intact PMN's is used as a measure of superoxide
formation. Preliminary experiments indicated lin-
earity of superoxide anion production with time and
cell concentration. Dose-response studies with
PMA indicated essentially maximal stimulation
with 5 jsg/ml of PMA, similar to that reported re-
cently [44].
Polypropylene tubes (Falcon Plastics, Division of
BioQuest, Oxnard, California) were prepared with a
standard reaction mixture of 10% fresh serum, I x
106 PMN's, and HBSS sufficient to make the final
volume 1 ml. After a 10-mm preincubation at 37° C
in an oscillating water bath, 1.5 mis'i ferricyto-
chrome c [45] (type VI, Sigma Chemical Co., St.
Louis, Missouri) and either 5 g!ml PMA or DMSO
(final concentration, 0.25%) were added to the in-
cubation mixture. Reaction mixtures, one pair with
and one pair without added SOD (Sigma Chemical
Co., St. Louis, Missouri) at a final concentration of
100 pg/ml were used. Fifteen minutes after the addi-
tion of ferricytochrome c, incubations were termi-
nated by placing the tubes immediately on ice. Leu-
kocytes were removed by centrifugation at 4° C (x
lSOOg x 10 mm). Cell-free supernatants were kept
on ice or stored at —20° C before being assayed [45,
46]. For the determination of reduced ferricyto-
chrome c, 400 pi of supernatant was diluted with
800 1.d of 0.1 M phosphate buffer (pH, 7.4), and the
absorbance was determined at 549 nm (Perkin-El-
mer model 55B spectrophotometer) [46]. The fern-
cytochrome c in each sample then was oxidized
fully by the addition of a few grains of sodium fern-
cyanide, and the difference between the two read-
ings was used to calculate the amount of reduction
that had occurred. Results from duplicate tubes
were averaged. The results are expressed as the
change in absorbance per centimeter of path per 15
mm.
Preparation of compounds. PMA was dissolved
in DMSO at a concentration of 2 mglml and frozen
in small aliquots at —80° C. On the day of each ex-
periment, PMA was thawed and diluted 1:10 in 0.1
M sodium acetate buffer (pH, 6.5) [47, 48]. DMSO
was diluted 1:10 in 0.1 M sodium acetate buffer. Lu-
minol was dissolved in phosphate buffered saline
and femcytochrome c in HBSS.
Statistics. Unpaired Student's t test and, where
appropriate, paired tests were used for statistical
analysis, as indicated in figures and tables.
Results
The mean age of the patients in the study was 52
2 years, and the mean period of regular hemo-
dialysis treatment was 2.5 0.5 years. Patients
were dialyzed three times per week, for a total of 12
to 18 hours a week, with a hollow fiber capillary
dialyzer having a surface area of 1.5 m2. The etiol-
ogy of end-stage renal disease in patients included
hypertension, chronic glomerulonephritis, poly-
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cystic kidney disease, tubular interstitial disease,
and diabetes mellitus. The mean predialysis blood
urea nitrogen was 79 4 mg/dl, and the mean serum
creatinine was 14.7 1.4 mg/dl. Controls were age-
matched healthy adult volunteers with a mean age
of 48 2 years. Patients were taken off their medi-
cations 1 to 3 days prior to the study and had no
clinical evidence of infection at the time of study.
Chemiluminescence (CL). Background cpm ob-
tained on vials containing only HBSS, serum, and
luminol (4000 to 6000 cpm) were deducted from all
data as presented. The CL in Figs. 1—5 represents
resting values and the increase above resting values
(phorbol stimulated value minus resting value).
Control PMN's in autologous serum produced low
levels of light emission in the resting state (Fig. 1).
In response to stimulation with PMA, a marked
increase in light emission occurred, with peak val-
ues obtained at 20 mm and a gradual decline there-
after (Fig. 1). This pattern of response is similar to
that reported by others [18, 30].
Resting values of CL from PMN's of CHD pa-
tients studied in autologous serum were higher than
those from control PMN's at every time interval.
Response by patient PMN's to stimulation with
PMA exhibited significantly (P <0.05) less of an
increase over the resting values than did control
cells; the peak increase at 20 mm, being 60 5 x
I0 cpm for patients as compared with 76 5 x l0
cpm for controls. This difference was significant
(P <0.05) at all subsequent time intervals (Fig. 1).
In about one third of the patients, the peak CL value
was decreased by 40% or greater compared with
controls (data not shown). Trypan blue exclusion
was repeated at the end of each experiment, with
no difference between patient and control PMN's.
Crossincubation studies were performed to eval-
uate the effects of serum from CHD patients on light
emission. These studies were run simultaneously,
cells from CHD patients being placed in either au-
tologous or control serum. As shown in Fig. 2, the
resting CL was significantly (P < 0.05) lower with
CHD cells in control serum when compared with
CHD cells in autologous serum. Light emission
from patient neutrophils in response to PMA was,
however, similar in autologous and control serum.
This lack of difference was observed both in the
PMA-stimulated value (data not shown) and the
increase over resting value (Fig. 2), the peak in-
crease being 62 5 x 1ff3 cpm in autologous serum
and 63 6 x 10 cpm in control serum. Crossincu-
bation studies with control PMN's were conducted
in an identical fashion with PMN's in either autolo-
gous or patient serum. Resting values of light emis-
sion from control PMN's were significantly (P <
0.05) elevated in the presence of patient serum.
There was, nonetheless, no difference either in the
PMA-stimulated CL or in the increase between con-
trol cells placed in either autologous serum (peak in-
crease, 76 5 x l0 cpm) or patient serum (peak in-
crease, 80 7 x l0 cpm) (Fig. 3). These results
show that the resting values of light emission are in-
creased by serum from CHD patients, but the patient
serum does not alter response to PMA stimulation
by either patient or control PMN's. This is further
shown in Fig. 4, which compares CL from both pa-
tient and control PMN's in serum from CHD pa-
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Fig. 1. Light emission by normal and CHD leukocytes in autolo-
gous serwn. In Figs. 1 through 5, open symbols represent rest-
ing values and closed symbols always represent the increase
(phorbol-stimulated values minus resting value) in response to
PMA. Also in Figs. 1 through 5, solid lines indicate that
the leukocytes were studies in control serum, and inter-
rupted lines indicate that they were placed in serum from CHD
patients. Total reaction mixture of 2 ml contained I x 106
PMN's, luminol in a final concentration of 1.5 >< and PMA
in a final concentration of 5 ugIml. All values represent the mean
SaM - Anasterisk (*)denotes P < 0.05 or greater level of signif-
icance, by group t test.
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Fig. 2. Light emission by leukocytes from CHI) patients placed
in either autologous or control serum. Resting values are in-
dicated by open symbols, the increase in response to PMA by
closed symbols. For other details see caption for Fig. 1. Studies
in control and autologous serum were made using the same leu-
kocyte preparations in simultaneous experiments. All values rep-
resent the mean SEM. An asterisk (*) denotes P < 0.05 or
greater level of significance, by paired t test.
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Fig. 3. Light emission by leukocytes from controls placed in ei-
ther autologous or patient serum. Resting values are indicated by
open symbols; the increase in response to PMA, by closed sym-
bols. For other details see caption for Fig. 1. Studies in au-
tologous and patient serum were made using the same leu-
kocyte preparations in simultaneous experiments. All values rep-
resent the mean SEM. An asterisk (*) denotes P < 0.05 or
greater level of significance, by paired t test.
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tients. The resting values of light emission for the
two cell populations are now essentially identical,
and a significant (P <0.05) difference in the in-
crease is evident, with the peak increase being 80
7 X l0 cpm at 20 mm for controls and 60 5 x l0
cpm at 20 mm for CHD patients. These differences
persist at all time intervals thereafter (Fig. 4).
Cells from CHD patients were studied in autolo-
gous serum postdialysis and were compared with
the predialysis values in the same patients (Fig. 5).
Resting levels of light emission were significantly (P
<0.05) less postdialysis. But, the PMA-stimulated
values or the increase were not significantly dif-
ferent, the increase at 20 mm predialysis being 60
6 x 10 cpm and that for postdialysis being 62
7 x l0 cpm (Fig. 5). To examine whether the lower
resting CL values postdialysis were due to changes
in serum or to the effect of hemodialysis on PMN's,
we compared light emission by control PMN's in
pre- and post-dialysis serum. Control PMN's had a
lower resting CL (7.34 2.2 x 10 cpm, N = 9) in
postdialysis serum compared with predialysis serum
(16.58 2.22 X 10 cpm, N = 15). The increase
above resting at 20 mm was similar in pre- and post-
dialysis serum (control PMN's postdialysis serum,
80.99 8.39 X 10 cpm, N = 9; predialysis serum,
79.51 6.88 X 10 cpm, N = 15).
Superoxide generation. No significant difference
in either resting or PMA-stimulated SOD-inhib-
itable ferricytochrome c reduction was found be-
tween PMN's from CHD patients and controls
(Table 1). In absence of SOD, the reduction of fer-
ricytochrome c by PMN's from CHD patients in
both the resting state and in the presence of PMN's
was significantly (P < 0.05) greater than that by
control cells (Table 1). This difference was due to
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Fig. 4. Light emission by control and CHD leukocyles both
placed in serum from CHD patients. Resting values are indicated
by open symbols; the increase in response to PMA, by closed
symbols. For other details see caption for Fig. 1. All values
represent the mean SEM. An asterisk (*) denotes P < 0.05
or greater level of significance, by group t test.
the reduction of ferricytochrome c, which cannot be
inhibited by SOD (Table 1). To evaluate the role of
serum from CHD patients in this reduction of fer-
ricytochrome c, we did crossincubation studies
with patient cells in autologous and normal serum.
The results show that, in the presence of normal
serum, the reduction of ferricytochrome c that can-
not be inhibited by SOD is significantly (P <0.05)
less in both the resting state and in the presence of
PMA (Table 2).
Discussion
Phagocytosis in PMN's from patients with uremia
has been reported to be either normal [10, 11] or
impaired [8, 9]. To study components of the respira-
tory burst dissociated from phagocytosis, we elect-
ed to use a soluble agent, PMA, to stimulate the
PMN's. PMA, the active principle of croton oil, has
been shown to stimulate all aspects of the respira-
tory burst, including increased production of super-
N9
Time, rn/n
Fig. 5. Light emission by leukocytes from CHD patients in autol-
ogous serum predialysis and in the same patients postdialysis.
Resting values are indicated by open symbols; the increase in
response to PMA, by closed symbols. For other details see
caption for Fig. 1. All values represent the mean SEM. An
asterisk (*) denotes P < 0.05 or greater level of significance, by
group t test.
oxide anion, hydrogen peroxide, stimulation of the
hexose monophosphate shunt, and CL. PMA has
also been shown to mimic effects of particles on
neutrophil vacuole formation and to be useful in de-
tecting defective PMN's in patients with chronic
granulomatous disease [18, 47, 48].
The light emission studies were done with lumi-
nol (which is converted to an excited amino-
phthalate ion in presence of oxidizing species—a re-
action with high quantum efficiency) to amplify the
CL [16]. This allows studies to be done with fewer
cells [16, 34], thus requiring less blood to be
drawn— a distinct advantage in studying CHD pa-
tients. In additon, compared with native CL, it has
been shown recently that luminol-amplified CL pro-
vided a better discrimination in detection of carrier
relatives of patients with chronic granulomatous
disease [35]. Thus, the luminol-amplified CL assay
appears to be useful to detect even subtle defects in
oxidative metabolism in phagocytic cells [35].
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Table 1. Ferricytochrome c reduction by leukocytes in autologous seruma
Resting', absorbance per 15 mm PMA(5 Lg/ml)', zabsorbanceper 15 mm
SOD-inhibitable SOD-inhibitable
Without With cytochrome c Without With cytochrome c
SOD SOD reduction SOD SOD reductione Increase"
Controls 0.174 0.022 0.134 0.022 0.048 0.012 0.440 0.020 0.144 0.018 0.298 0.020 0.250 0.022
(N = 24) (N = 24) (N = 24) (N = 24) (N = 24) (N = 24) (N = 24)
Patients 0.272e 0.026 0.218 0.024 0.052 0.008 0.518 0.020 0.236e 0.024 0.282 0.024 0.228 0.024
(N = 24) (N = 24) (N = 24) (N = 24) (N = 24) (N = 24) (N = 24)
Values are the means SEM. Abbreviations are: PMA, phorbol myristate acetate; SOD, superoxide dismutase.
b Incubation mixture contained 1 x 106 leukocytes in a total volume of 1 ml. From this, 0.4 ml of supernatant was diluted with 0.8 ml
phosphate buffer and the OD read at 549 nm. The amount of reduced ferricytochrome c was obtained with the addition of sodium
ferricyanide. Values represent the change in OD per 15 mm.
SOD inhibitable ferrycytochrome c reduction is taken as a measure of superoxide anion production.
d Change in increase represents superoxide anion production in response to PMA above the resting state.
p 0.05 or greater level of significance, group t test.
Table 2. Ferricytochrome c reduction by patients' leukocytes in analogous and control seruma, b
Resting, absorbance per 15 mm PMA (5 g/m1), absorbance per 15 mm
SOD- SOD-
inhibitable inhibitable
Without With cytochrome c Without With cytochrome c
SOD SOD reduction SOD SOD reduction Increase
Patients' leukocytes
autologous serum 0.198 0.024 0.140 0.022 0.060 0.012 0.508 0.028 0.164 0.020 0.344 0.030 0.284 0.032
(N= 13) (N= 13) (N= 13) (N= 13) (N= 13) (N= 13) (N= 13)
0.154c 0.020 0.086c 0.018 0.070 0.016 0.496 0.034 0.108 0.016 0.386 0.030 0.316 0.030
(N = 13) (N = 13) (N = 13) (N = 13) (N = 13) (N = 13) (N = 13)
a Values are the means SEM. Abbreviations are: PMA, phorbol mynstate acetate; SOD, superoxide dismutase. Refer to footnotes of
Table 1, for details.
b Patients' leukocytes were studied in autologous and control serum in the same experiment.
P  0.05 or greater level of significance, paired t test.
With luminol-amplified CL, our results show that
PMN's from patients on CHD have a higher resting
level of CL and that both the phorbol-stimulated
values and the increase-above-resting values in re-
sponse to stimulation by PMA are lower than are
those of control PMN's when cells are studied in
autologous serum (Fig. 1).
Elevated values of resting light emission by neu-
trophils from patients on CHD appear to be related
to a factor(s) in the serum because CL by patient
PMN's decreases when they are placed in control
serum, and CL by control cells increases when
placed in patient serum. No correlation was noted
with blood urea nitrogen, creatinine, calcium, or
phosphate (data not shown). The factor(s) also ap-
pear to be dialyzable because, compared with pre-
dialysis values, there is a significant (P <0.05) de-
crease in the postdialysis resting CL (Fig. 5). The
lower resting CL is due to changes in serum rather
than changes in PMN's, because control PMN's al-
so had a lower resting CL in postdialysis compared
with predialysis serum.
Our findings are similar to those in a preliminary
report by Tuma et al [49] in which they have found
higher resting levels of CL in cells from patients on
CUD with secondary hyperparathyroidism; this in-
creased light emission was due to serum effects,
as indicated by their crossincubation studies. In
their study, also no correlation was noted with cal-
cium, phosphate, blood urea nitrogen, or creati-
nine. Although we did not examine the factors in
serum causing the elevated resting values, Tuma et
al found that in their patients on CHD, levels of
resting CL decreased following parathyroidectomy.
They interpreted their results to mean that PMN's
from CHD patients with secondary hyperparathy-
roidism have augmented metabolic activity, as a re-
sult of parathyroid hormone and/or its fragments
Patients' leukocytes
control serum
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[49]. Other studies also have suggested augmented
metabolic activity in unstimulated PMN' s from pa-
tients with uremia [11, 50].
Both phorbol-stimulated values and the increase
above resting values for light emission produced by
PMN's from patients on CHD were lower when com-
pared with control cells following stimulation by
PMA (Fig. 1). This difference in light emission fol-
lowing stimulation with PMA was not due to differ-
ences in resting values, because when both patients
and control cells are placed in serum from CHD pa-
tients, significant (P < 0.05) differences in the in-
crease above resting persist, whereas resting values
were essentially identical (Fig. 4). Differences in
light emission cannot be attributed to differential cell
survival because viability was checked at the end of
each experiment by using trypan blue exclusion and
was found to be identical between patient and con-
trol PMN's. Clearly, observed differences in light
emission cannot be explained on the basis of im-
paired phagocytosis by neutrophils from patients on
CHD because a soluble stimulus, PMA, was used in
the study. Because the marked increase in CL fol-
lowing PMA stimulation is related to the respiratory
burst, the small contamination with lymphocytes in
our preparations is unlikely to account for the ob-
served differences between CHD patients and con-
trols. In addition, purity of PMN' s obtained from
controls and CHD patients was checked carefully
and was found to be similar. Crossincubation stud-
ies show that the stimulated CL in CHD patients'
PMN's is not improved by control serum (Fig. 2)
and, conversely, that serum from CHD patients
does not reduce stimulated CL by control cells (Fig.
3). These results indicated that the diminished CL
response appears intrinsic to the PMN' s and at least
is not due to some immediate effect of serum from
CHD patients. Further, no improvement in CL re-
sponse was noted immediately after dialysis.
Ferricytochrome c reduction in the resting state
and in response to PMA stimulation was measured
in the presence and absence of SOD. SOD-inhib-
itable femcytochrome c reduction was used as a
measure of superoxide anion production, and no
significant difference in these values was found be-
tween neutrophils from patients and from controls
(Table 1). In the absence of SOD, a significant (P <
0.05) difference in ferricytochrome c reduction was
noted, the patient values being higher than those of
control. This is similar to higher levels of NBT re-
duction noted in earlier studies of PMN' s from pa-
tients on CHD [11, 50]. The observed difference in
ferricytochrome c reduction is accounted for by the
reduction of ferricytochrome c which cannot be in-
hibited by SOD (Table 1). In crossincubation stud-
ies, the reduction of ferricytochrome c that cannot
be inhibited by SOD becomes significantly (P <
0.05) less in both the resting state and in the pres-
ence of PMA when patient cells are placed in con-
trol serum as opposed to autologous (Table 2).
These studies indicate that the serum of CHD pa-
tients contains a factor(s) that cause reduction of
ferricytochrome c independently of superoxide an-
ion.
Most studies indicate that the CL response in
PMN's is related to the production of reactive
forms of oxygen, including superoxide anion, hy-
drogen peroxide, hydroxyl radical, and singlet oxy-
gen [30—32]. Interference with the generation or
subsequent activity of these forms of oxygen could
be reflected by alterations in the PMN's ability to
generate CL. Thus, the impaired CL response in
PMN' s from patients with chronic granulomatous
disease [33] is due to inability to generate super-
oxide anion and other oxygen species in response to
stimulus [13, 29]. But, in MPO-deficient PMN's and
in the presence of azide (MPO inhibitor), the CL
response is diminished in spite of normal or even
higher production or superoxide anion and hydro-
gen peroxide [39, 40]. In addition, the ascorbate
peroxide (MPO independent) system also may con-
tribute to CL [51]. Our results, which show a nor-
mal extracellular production of superoxide anion
(SOD inhibitable ferricytochrome c reduction),
along with other studies showing normal NBT re-
duction (a measure of intracellular superoxide anion
production), implicate mechanisms other than su-
peroxide anion production in the reduced CL in
PMN's from CHD patients observed in our study.
Regardless of the mechanisms involved, CL has
been shown to correlate well with the antimicrobial
activity of PMN's. Thus, PMN's from patients with
chronic granulomatous disease and MPO defi-
ciency, as well as PMN's in the presence of azide
(which inhibits MPO) all have reduced CL and im-
paired antimicrobial activity [29, 33, 39, 40]. In as-
corbate-hydrogen peroxide bactericidal system (an
MPO-independent CL), a positive correlation be-
tween CL and bactericidal activity was shown [51].
In addition, in a recent comparative investigation of
in vitro bacterial killing and CL by pharmacolog-
ically altered PMN's, in every instance, a parallel
modulation of CL and killing was observed [36].
Summary. Our results show that the resting CL
from PMN's from CHD patients is higher and that
this is due to factors present in their serum. In addi-
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tion there is reduced CL response to a soluble stim-
ulus, which appears to be due to mechanisms other
than diminished superoxide anion production. The
mechanisms responsible for the observed dif-
ferences and whether they are related to effects of
uremia itself or to effects of chronic hemodialysis
treatment are not known. The reduced CL response
may be, however, a reflection of a subtle defect in
PMN oxidative potential. This along with other de-
fects in PMN function [4-9] may account, at least in
part, for the higher susceptibility of these patients
to bacterial infection.
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